Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSGJ-706 in advanced gastrointestinal cancers
NCT07233850Phase 2Not yet recruiting
- Sponsor
- 3SBio
- Start
- Nov 2025
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of SSGJ-706 in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), esophageal cancer, sponsored by 3SBio. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
SSGJ-706
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomacolorectal cancer (CRC)pancreatic ductal adenocarcinoma (PDAC)esophageal cancer
Beyond the preview
Go deeper on NCT07233850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07233850.